You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
施貴寶(BMY.US)重磅癌症藥物Opdivo在歐洲獲得三種適應症批准
格隆匯 04-05 19:24
格隆匯4月5日丨施貴寶(BMY.US)週二宣佈,歐盟批准了其重磅癌症藥物Opdivo的三份擴大批准申請。公司表示,委員會批准了Opdivo用於成人肌肉浸潤性尿路上皮癌的輔助治療,這些患者的腫瘤細胞PD-L1表達量為1%,且在接受根治性切除後復發風險較高。這使其成為歐盟在這種情況下批准的首個輔助免疫治療方案。委員會還批准了Opdivo與化療以及與公司抗癌藥物Yervoy聯合用於不能切除的晚期、復發或轉移性食管鱗狀細胞癌(PD-L1表達率為1%)的一線治療。該公司表示,在這組患者中,兩種基於opdivo的聯合治療顯示出比單獨化療更好的生存效益。Opdivo利用人體自身的免疫系統來對抗癌症,目前已在超過65個國家獲得批准,用於治療多種癌症,去年的收入超過75億美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account